Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.
A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.
Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.
Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.
Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.
The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.
People who elect to undergo sunless tanning tend to continue behaviors that could increase their risk of skin cancer.
The use of multiple sun protection measures was defined as the use of 2 or more of these measures more than 50% of the time when the individual was outdoors.
Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in MelanomaJuly 12, 2018
Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.
According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.
The FDA based their approval on findings from the phase 3 COLUMBUS study, in which researchers randomly assigned patients with BRAF V600-mutant melanoma to receive encorafenib plus binimetinib, encorafenib, or vemurafenib.
Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Results from a small study show that PD-1 inhibitors could work synergistically with radiosurgery to promote slightly longer survival times.
If approved, the new indication could mean pembrolizumab could be used for patients with melanoma.
Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.
Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.
When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
Victor Sandor, MD, discusses the treatment combination at the ASCO 2018 meeting in Chicago.
Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.
The FDA based its approval on the results of the phase 3 COMBI-AD study.
KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Improvement in RFS was seen regardless of PD-L1 status.
Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.
This systematic review analyzed the current evidence on the benefits and harms of behavioral counseling for skin cancer prevention and found that these interventions can increase sun protection behavior.
One death possibly related to treatment was, however, noted in the combination group.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC